Orca Bio’s TREGZITM Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies

MENLO PARK, Calif.--(BUSINESS WIRE)--The FDA has approved TREGZI, the first and only precision-engineered cell therapy for allogeneic transplant in adults with hematological malignancies.